The global sickle cell disease treatment market size reached USD 4.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 13.1 Billion by 2033, exhibiting a growth rate (CAGR) of 13.26% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 4.0 Billion |
Market Forecast in 2033
|
USD 13.1 Billion |
Market Growth Rate 2025-2033 | 13.26% |
Sickle cell disease (SCD) is a genetic red blood cell (RBC) disorder that affects hemoglobin, a protein that carries oxygen throughout the body. It leads to many complications, such as acute chest syndrome, anemia, and vaso-occlusive crisis (VOC). At present, blood and bone marrow transplant is commonly suggested by doctors for treating SCD. It involves replacing affected bone marrow with a healthy substitute received from a donor. Other effective treatments, such as medications and blood transfusions, are also being utilized as they can reduce specific symptoms and prolong the life of patients.
A considerable increase in the number of individuals suffering from SCD represents one of the significant factors influencing the demand for new medications that can treat the condition effectively. As a result, the health regulatory authorities of numerous countries are focusing on fast-track approval of new treatment methods. For instance, the United States Food and Drug Administration (USFDA) approved a new medicine in 2019 to reduce the pain experienced by adults and children with SCD. Additionally, government authorities are supporting research and development (R&D) activities to encourage researchers and pharmaceutical companies to develop novel treatments. For instance, researchers at the National Heart, Lung, and Blood Institute (NHLBI) in the US are working on genetic therapies that can restore a missing gene or add a new DNA strain to improve the functioning of cells. These innovations, along with the rising disposable incomes and the growing awareness among individuals about the available healthcare services, are anticipated to contribute to market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global sickle cell disease treatment market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on treatment type and end user.
Breakup by Treatment Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc. and Sangamo Therapeutics.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Treatment Type, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc., Sangamo Therapeutics |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global sickle cell disease treatment market was valued at USD 4.0 Billion in 2024.
We expect the global sickle cell disease treatment market to exhibit a CAGR of 13.26% during 2025-2033.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective treatment procedures for sickle cell disease to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals or medical equipment.
The rising prevalence of sickle cell disease, along with the growing demand for new medications that can treat the condition effectively, to reduce specific symptoms and prolong the life of patients, is primarily driving the global sickle cell disease treatment market.
Based on the treatment type, the global sickle cell disease treatment market has been segregated into blood transfusion, pharmacotherapy, and bone marrow transplant. Among these, blood transfusion currently holds the largest market share.
Based on the end user, the global sickle cell disease treatment market can be bifurcated into hospitals, diagnostic centers, and others. Currently, hospitals exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global sickle cell disease treatment market include AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc., and Sangamo Therapeutics.